MHA Statement on Approval of Johnson & Johnson COVID-19 Vaccine

Posted on February 27, 2021

The following statement can be attributed to Brian Peters, CEO of the Michigan Health & Hospital Association. 

MHA CEO Brian PetersThe approval of an emergency use authorization for the Johnson & Johnson COVID-19 vaccine is another significant step toward ending the pandemic. The availability of a safe and effective single-dose vaccine will help Michigan vaccinate our population, especially those vulnerable and harder to reach residents, more quickly. The Johnson & Johnson vaccine demonstrated complete protection against COVID-19-related hospitalization and death 28 days post-vaccination in its clinical trials. The addition of a third approved vaccine will also help alleviate existing vaccine supply constraints and quicken the pace of administering vaccines.

Hospitals will continue to assist with vaccination efforts as more details are released by federal and state entities about how this new vaccine should be put to use.


Photographs

  • MHA Statement on Approval of Johnson & Johnson COVID-19 Vaccine

Tags: Brian Peters, COVID-19, Food and Drug Administration, Johnson and Johnson vaccine

Posted in: News Releases, Issues in Healthcare, Member News, Top Issues - Healthcare

MHA Updates Delivered to You

Subscribe to the MHA Monday Report weekly newsletter or our podcast, the MiCare Champion Cast, to keep informed about the latest healthcare news and events in Michigan.

MHA Monday Report
Contact us to subscribe

MiCare Champion Cast
iTunes | SoundCloud


Media Inquiries

Contact the MHA at
(517) 703-8601

Read the MHA policy on publication via MHA media.

MHA 100 Year Anniversary

Watch the video »